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BACKGROUND: Sodium-glucose cotransporter 2 inhibitors improve 
outcomes in patients with heart failure with reduced ejection fraction, but 
additional information is needed about whether glycemic status influences the 
magnitude of their benefits on heart failure and renal events.
METHODS: Patients with Class II–IV heart failure and a left ventricular 
ejection fraction ≤40% were randomized to receive empagliflozin (10 mg 
daily) or placebo in addition to recommended therapy. We prespecified 
a comparison of the effect of empagliflozin in patients with and without 
diabetes.
RESULTS: Of the 3730 patients enrolled, 1856 (50%) had diabetes, 1268 
(34%) had prediabetes (hemoglobin A1c [HbA1c] 5.7–6.4%), and 606 
(16%) had normoglycemia (HbA1c <5.7%). The risks of the primary outcome 
(cardiovascular death or hospitalization for heart failure), total hospitalizations 
for heart failure, and adverse renal outcomes were higher in patients 
with diabetes, but were similar between patients with prediabetes and 
normoglycemia. Empagliflozin reduced the risk of the primary outcome in 
patients with and without diabetes (hazard ratio, 0.72 [95% CI, 0.60–0.87] 
and 0.78 [95% CI, 0.64–0.97], respectively, P-interaction=0.57). Patients 
with and without diabetes also did not differ with respect to the effect of 
empagliflozin on total hospitalizations for heart failure, on the decline in 
estimated glomerular filtration rate over time, and on the risk of serious 
adverse renal outcomes. Among these end points, the effects of the drug did 
not differ in patients with prediabetes or normoglycemia. When analyzed as a 
continuous variable, baseline HbA1c did not significantly modify the benefits 
of empagliflozin on the primary outcome (P-interaction=0.40). Empagliflozin 
did not lower HbA1c in patients with prediabetes or normoglycemia and was 
not associated with increased risk of hypoglycemia.
CONCLUSIONS: In EMPEROR-Reduced (Empagliflozin Outcome Trial 
in Patients With Chronic Heart Failure With Reduced Ejection Fraction), 
empagliflozin significantly improved cardiovascular and renal outcomes in 
patients with heart failure and a reduced ejection fraction, independent of 
baseline diabetes status and across the continuum of HbA1c.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: 
NCT03057977.
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Unlike other antihyperglycemic agents, sodium-glucose cotransporter 2 (SGLT2) inhibitors have consistently been shown to reduce the risk of 
heart failure hospitalizations and serious renal out-
comes among patients with diabetes.1–3 These sub-
stantial cardio-renal benefits cannot be explained by 
the antihyperglycemic action of SGLT2 inhibitors. 
Therefore, it has been suggested that SGLT2 inhibi-
tors exert broad cardioprotective and nephroprotective 
effects, which would be apparent in patients with or 
without diabetes.4
In the DAPA-HF trial (Dapagliflozin and Prevention 
of Adverse Outcomes in Heart Failure), dapagliflozin 
was shown to reduce the risk of worsening heart 
failure events and cardiovascular death independent 
of diabetes status.5,6 However, the DAPA-HF trial did 
not comprehensively report the influence of diabetes 
on the renal effects of dapagliflozin or the influence 
of prediabetes; furthermore, the trial enrolled primar-
ily patients who had mild to moderate left ventricular 
systolic dysfunction and increases in natriuretic pep-
tides. EMPEROR-Reduced (Empagliflozin Outcome Trial 
in Patients With Chronic Heart Failure With Reduced 
Ejection Fraction) evaluated the effect of empagliflozin 
in patients with heart failure, including those with more 
severe left ventricular systolic dysfunction and more se-
verely impaired kidney function, and the trial identified 
the effect of the drug on renal outcomes as a major 
outcome variable.7 Empagliflozin reduced the risk of 
major adverse heart failure and renal outcomes when 
added to inhibitors of the renin-angiotensin system and 
β-blockers and regardless of background therapy with 
mineralocorticoid receptor antagonists and angiotensin 
receptor/neprilysin inhibitors.8
In this prespecified analysis of EMPEROR-Reduced, 
we analyzed the efficacy and safety of empagliflozin 
on heart failure and renal events by baseline diabetes 




EMPEROR-Reduced (URL: https://www.clinicaltrials.gov; 
Unique identifier: NCT03057977) was a randomized, double-
blind, parallel-group, placebo-controlled, event-driven study. 
Patients were recruited into EMPEROR-Reduced between 
April 25, 2017, and November 8, 2019, at 520 centers in 
20 countries. The design and conduct of this trial have been 
published previously.7 The trial was approved by the ethics 
committee at each study site and all patients provided written 
informed consent.
Study Patients
Participants included patients ≥18 years or older who had 
chronic heart failure (New York Heart Association func-
tional Class II, III, or IV) with a left ventricular ejection frac-
tion ≤40%. To enroll patients at increased risk of events, the 
number of patients with an ejection fraction >30% was lim-
ited by requiring that they had been hospitalized for heart 
failure within 12 months or had exceptionally high levels of 
NT-proBNP (N-terminal prohormone B-type natriuretic pep-
tide; ie, >1000 pg/mL or >2500 pg/mL in those with an ejec-
tion fraction of 31% to 35% or 36% to 40%, respectively); 
these thresholds were doubled in patients with atrial fibril-
lation. Patients were receiving all appropriate treatments 
for heart failure as available and tolerated. Exclusion criteria 
included symptomatic hypotension, systolic blood pressure 
of <100 mm Hg or ≥180 mm Hg, or an estimated glomeru-
lar filtration rate (eGFR) <20 mL/min/1.73 m2. After a 4- to 
28-day screening period, patients who fulfilled eligibility 
criteria were randomized double-blind (in a 1:1 manner) to 
receive placebo or empagliflozin 10 mg daily in addition to 
their usual therapy for heart failure.
For this prespecified subgroup analysis, patients were 
categorized as having diabetes if they had a history of the 
diagnosis or if 1 pretreatment HbA1c was at least 6.5% (≥48 
mmol/mol). Among those without diabetes, patients were 
classified as having prediabetes if they had an HbA1c of 5.7% 
to 6.4%, and they were considered to have normoglycemia 
if they had all pretreatment HbA1c of <5.7%. Randomization 
Clinical Perspective
What Is New?
• In the placebo-controlled EMPEROR-Reduced 
(Empagliflozin Outcome Trial in Patients With 
Chronic Heart Failure With Reduced Ejection Frac-
tion), the addition of empagliflozin to recom-
mended heart failure therapy reduced the risk of 
cardiorenal outcomes in patients with heart failure 
with reduced ejection fraction with and without 
diabetes.
• The risks of these cardiorenal outcomes were higher 
in patients with diabetes but were similar between 
patients with prediabetes and normoglycemia.
• These favorable heart failure and renal effects of 
empagliflozin were consistent in patients with or 
without diabetes and across the spectrum of A1C.
• Empagliflozin did not lower glycohemoglobin in 
patients without diabetes and was not associated 
with increased risk of hypoglycemia.
What Are the Clinical Implications?
• The heart failure and renal benefits of empagliflozin 
in patients with heart failure and a reduced ejection 
fraction are present both in patients with and with-
out diabetes and are not influenced by baseline lev-
els of glycohemoglobin.
• Decisions regarding the use of empagliflozin for 
the treatment of heart failure and a reduced ejec-
tion fraction should not be driven by the glycemic 
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was stratified on the basis of glycemic status at screen-
ing (diabetes, prediabetes, or normoglycemia), geographic 
region (North America, Latin America, Europe, Asia, other), 
and eGFR (eGFR by the Chronic Kidney Disease Epidemiology 
Collaboration at screening < or ≥60 mL/min/1.73 m2). After 
randomization, patients were periodically evaluated for effi-
cacy, vital signs, laboratory tests, and adverse events. These 
assessments included the Kansas City Cardiomyopathy 
Questionnaire (KCCQ), systolic blood pressure, hemoglobin, 
body weight, HbA1c, NT-proBNP, and renal function.
Trial End Points
The primary end point of EMPEROR-Reduced was the time-
to-first-event analysis of the combined risk of cardiovascular 
death or hospitalization for heart failure. This analysis was 
based on adjudicated events, as assessed by a clinical event 
committee, which applied prespecified definitions and was 
blinded to the treatment assignment. The key secondary end 
points of the study were the total number of adjudicated 
hospitalizations for heart failure (including first and recurrent 
events) and the slope of the change in eGFR during double-
blind treatment. We prespecified 2 additional assessments of 
renal function. First, in 966 patients, we analyzed eGFR 23 
to 45 days after the withdrawal of the study medication at 
the end of double-blind treatment. Changes in eGFR from 
prerandomization to the off-treatment visit allowed for an 
assessment of the long-term effects of treatment on renal 
function unconfounded by the presence of an SGLT2 inhibitor. 
Second, a composite renal end point was defined as the need 
for chronic dialysis or renal transplant or a ≥40% decrease in 
eGFR or a sustained eGFR <15 mL/min/1.73 m2 (if the baseline 
eGFR was ≥30) or <10 mL/min/1.73 m2 (if the baseline eGFR 
was <30 mL/min/1.73 m2). We evaluated the effects of treat-
ment on the individual components of the primary end point.
Changes between the treatment groups in the KCCQ clini-
cal summary score, body weight, blood pressure, hemoglo-
bin and glycohemoglobin, and NT-proBNP were assessed at 
52 weeks. Safety analyses included serious adverse events, 
adverse events leading to discontinuation of study drug, and 
specified adverse events of interest (hypotension, volume 
depletion, hypoglycemia, diabetic ketoacidosis, limb amputa-
tions, fractures, acute renal failure, and genital and urinary 
tract infections).
Statistical Analyses
For time to first event analyses, differences between the pla-
cebo and empagliflozin groups for the primary end point 
were assessed for statistical significance using a Cox propor-
tional hazards model, with prespecified covariates of age, sex, 
geographical region, diabetes status at baseline, left ventricu-
lar ejection fraction, and estimated glomerular filtration rate 
at baseline. These analyses were performed according to the 
intention-to-treat principle for all randomized patients and 
included data up to the end of the planned treatment period. 
For the analysis of total (first and repeated) events, between-
group differences were assessed using a joint frailty model, 
with cardiovascular death as a competing risk. For the analy-
sis of changes in eGFR, KCCQ scores, vital signs, and labora-
tory measurements, treatment effects were assessed based 
on changes from baseline using a mixed model for repeated 
measures. Between-group difference in the slope of change in 
eGFR were analyzed using a random intercept random slope 
model. KCCQ as well as eGFR slope and mixed model for 
repeated measures were analyzed using on-treatment data. 
The mixed model for repeated measures, the slope model, 
and the joint frailty model included the same covariates as the 
Cox model. To assess the consistency of effects across sub-
groups, subgroup-by-treatment interaction terms were added 
in the models. Analyses for safety were performed including 
all the patients who had received at least 1 dose of empa-
gliflozin or placebo.
According to our prespecified statistical plan, analyses of 
the influence of glycemic status on the effect of empagliflozin 
on various outcomes and measurements were made primar-
ily by comparing patients with or without diabetes. Analyses 
were performed to evaluate and compare the effect of empa-
gliflozin in patients with diabetes, prediabetes, and normogly-
cemia (which were stratification variables in the trial). We also 
evaluated in exploratory analyses the effect of baseline HbA1c 
(as a continuous variable) on the effect of empagliflozin on 
first heart failure hospitalization or cardiovascular death 
assuming a linear relationship.
All analyses were performed using SAS, version 9.4 (SAS 
Institute). All P values reported are 2-sided, and P<0.05 was 
considered as statistically significant in all cases. No adjust-
ments for multiple testing were made.
Data Sharing
Data will be made available on request in adherence with 
transparency conventions in medical research and through 
requests to the corresponding author. The executive com-
mittee of EMPEROR has developed a comprehensive analy-
sis plan and numerous prespecified analyses, which will be 
presented in future scientific meetings and publications. At 
a later time point, the full database will be made available 




Of the 3730 patients who were randomly assigned to 
receive either placebo or empagliflozin, 1856 (50%) 
had diabetes, and of the patients without diabetes, 
1268 (34%) had prediabetes and 606 (16%) were nor-
moglycemic. When compared with patients without 
diabetes, those with diabetes were more likely to have 
a history of hospitalization for heart failure, New York 
Heart Association functional Class III symptoms, and a 
history of hypertension, and a higher proportion had 
eGFR<60 mL/min/1.73 m2 (Table 1). Patients with predi-
abetes had baseline characteristics similar to those with 
normoglycemia (Table I in the Data Supplement). The 
mean HbA1c was 7.4±1.6% in patients with patients 
with diabetes, 5.9±0.2% in patients with prediabetes, 
and 5.3±0.3% in normoglycemic patients. A total of 
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Table 1. Baseline Characteristics by Diabetes Status
 





Age, y 67.6±11.6 66.3±12.0 66.8±10.0 66.6±10.3
Female sex 227 (24.3) 238 (25.4) 210 (22.7) 218 (23.5)
Race
  White 679 (72.5) 665 (70.9) 646 (69.7) 639 (68.8)
  Black 66 (7.1) 71 (7.6) 57 (6.1) 63 (6.8)
  Asian 154 (16.5) 160 (17.1) 183 (19.7) 175 (18.8)
  Other or missing 37 (4.0) 42 (4.5) 41 (4.4) 52 (5.6)
Region
  North America 105 (11.2) 98 (10.4) 107 (11.5) 115 (12.4)
  Latin America 330 (35.3) 331 (35.3) 311 (33.5) 314 (33.8)
  Europe 344 (36.8) 349 (37.2) 332 (35.8) 328 (35.3)
  Asia 125 (13.4) 124 (13.2) 123 (13.3) 121 (13.0)
  Other 32 (3.4) 36 (3.8) 54 (5.8) 51 (5.5)
New York Heart Association functional classification
  II 742 (79.3) 733 (78.1) 657 (70.9) 668 (71.9)
  III 190 (20.3) 202 (21.5) 265 (28.6) 253 (27.2)
  IV 4 (0.4) 3 (0.3) 5 (0.5) 8 (0.9)
Body mass index, kg/m2 27.2±5.3 27.0±5.2 28.8±5.5 28.6±5.4
Heart rate, beats/min 69.7±11.6 70.9±12.1 72.3±11.6 72.2±11.3
Systolic blood pressure, mm Hg 122.0±15.9 119.9±14.9 123.2±15.9 122.9±15.6
HbA1c, % 5.8±0.4 5.7±0.4 7.4±1.6 7.4±1.6
Left ventricular ejection fraction, % 27.9±6.0 27.2±6.0 27.6±6.0 27.2±6.1
NT-proBNP, pg/mL 1882 (1071, 3251) 1908 (1164, 3529) 1894 (1093, 3572) 1937 (1151, 3501)
Principal cause of heart failure
  Ischemic 429 (45.8) 433 (46.2) 554 (59.8) 513 (55.2)
  Nonischemic 507 (54.2) 505 (53.8) 373 (40.2) 416 (44.8)
Medical history
  Hospitalization for heart failure in last 
12 months
261 (27.9) 260 (27.7) 316 (34.1) 314 (33.8)
  Atrial fibrillation* 354 (37.8) 382 (40.7) 310 (33.4) 323 (34.8)
  Hypertension 619 (66.1) 620 (66.1) 730 (78.7) 729 (78.5)
eGFR
  Mean, mL/min/1.73 m2 62.7±21.1 63.0±21.0 61.0±22.3 61.4±22.1
  Rate of <60 mL/min/1.73 m2 434 (46.4) 426 (45.4) 459 (49.5) 480 (51.7)
Device therapy
  Implantable cardioverter-defibrillator† 320 (34.2) 294 (31.3) 258 (27.8) 299 (32.2)
  Cardiac resynchronization therapy‡ 117 (12.5) 105 (11.2) 103 (11.1) 117 (12.6)
Heart failure medication
  ACE inhibitor 451 (48.2) 425 (45.3) 416 (44.9) 411 (44.2)
  ARB§ 213 (22.8) 227 (24.2) 238 (25.7) 230 (24.8)
  ARNI 178 (19.0) 193 (20.6) 162 (17.5) 194 (20.9)
  Diuretic|| 779 (83.2) 809 (86.2) 831(89.6) 829 (89.2)
  Mineralocorticoid receptor antagonist 667 (71.3) 694 (74.0) 639 (68.9) 661 (71.2)
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undiagnosed diabetes at baseline. Within each group, 
the baseline characteristics of the placebo and empa-
gliflozin groups were well-balanced (Table 1 and Table 
I in the Data Supplement). The median duration of fol-
low-up of 16 months was similar in the 3 groups.
The cumulative incidence curves for the primary out-
come and the 2 key secondary outcomes by diabetes 
status are shown in Figures  1–3. Figure  4 shows the 
cumulative incidence curves for the renal composite by 
diabetes status, whereas Figure 5 shows treatment ef-
fect of empagliflozin versus placebo on outcomes by 
glycemic status.
Primary Outcome and Total 
Hospitalizations for Heart Failure
When placebo event rates were considered, the inci-
dence of the primary composite outcome of cardio-
vascular death or hospitalization for heart failure was 
≈40% higher in diabetic patients than in nondiabetic 
patients (24.6 versus 17.6 per 100 patient-years of fol-
low-up, P<0.001; Figure 1 and Table 2), but there was 
no difference in risk between patients with prediabetes 
and those with normoglycemia (18.1 versus 16.6 per 
100 patient-years of follow-up, P=0.63; Figure 5).
The effect of empagliflozin on the primary outcome 
variable was not influenced by the presence or absence 
of diabetes (P-interaction=0.57). In patients with diabe-
tes, the primary outcome occurred in 200 of 927 (21.6%) 
in the empagliflozin group and 265 of 929 (28.5%) in 
the placebo group (hazard ratio [HR], 0.72 [95% CI, 
0.60–0.87]; Table 2). Among patients without diabetes, 
the primary outcome occurred in 161 of 936 (17.2%) in 
the empagliflozin group and 197 of 938 (21%) in the 
placebo group (HR, 0.78 [95% CI, 0.64–0.97]). Cumu-
lative incidence plots according to treatment are shown 
for patients with and without diabetes in Figure 1A and 
1B. The HRs for the effect of empagliflozin on the risk 
of cardiovascular death or heart failure hospitalization in 
patients with prediabetes and in those with normogly-
cemia were 0.76 (95% CI, 0.59–0.98) and 0.84 (95% 
CI, 0.58–1.21), respectively (P-trend=0.48); the estimate 
in patients with normoglycemia was imprecise because 
it was based on only 114 events (Figure 5). However, 
when considered as a continuous variable, HbA1c did 
not influence the effect of empagliflozin on the primary 
outcome when the relationship was evaluated assuming 
linearity (P-interaction=0.40; Figure 2).
A similar pattern of response was observed for to-
tal (first and recurrent) hospitalizations for heart failure. 
When the placebo event rates were considered, there 
were 337 hospitalizations for heart failure in the 1856 
patients with diabetes, but only 216 in the 1874 patients 
without diabetes, indicating an ≈50% to 60% higher 
rate in diabetic patients. The rate of heart failure hos-
pitalization in the patients with prediabetes was similar 
to that of those with normoglycemia (Figure 5). Empa-
gliflozin reduced the risk of a first or recurrent heart fail-
ure hospitalization to a similar degree in both diabetic 
and nondiabetic patients (HR, 0.65 [95% CI, 0.50–0.85] 
and 0.76 [95% CI, 0.57–1.01], respectively; Table 2 and 
Figure 3). Among the patients without diabetes, the HRs 
for the effect of empagliflozin on total hospitalizations for 
heart failure in patients with prediabetes and normogly-
cemia were 0.70 (95% CI, 0.50–0.99) and 0.90 (95% CI, 
0.55–1.48), respectively; the latter estimate was impre-
cise because it was based on only 125 events (Figure 5).
Renal Outcomes
When only the placebo groups were considered, the 
rate of decline in eGFR in patients with diabetes was 
Glucose-lowering therapy
  Any 4 (0.4) 7 (0.7) 683 (73.7) 687 (74.0)
  Biguanide 4 (0.4) 7 (0.7) 444 (47.9) 418 (45.0)
  Insulin 0 0 224 (24.2) 248 (26.7)
  Sulfonylurea 0 0 211 (22.8) 191 (20.6)
  DPP4 inhibitors 0 0 132 (14.2) 120 (12.9)
  GLP1 receptor analogues 0 0 13 (1.4) 6 (0.6)
Data given as mean±SD, n (%), or median (interquartile range). ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor 
blocker; ARNI, angiotensin receptor neprilysin inhibition; DPP4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; GLP1, 
Glucagon-like peptide-1 receptor agonist; HbA1c, hemoglobin A1c; and NT-proBNP, N-terminal prohormone B-type natriuretic peptide.
*Atrial fibrillation reported in any ECG before treatment intake or history of atrial fibrillation reported as medical history.
†Implantable cardioverter defibrillator with or without cardiac resynchronization therapy.
‡Cardiac resynchronization therapy with or without a defibrillator.
§Excluding valsartan when taken with sacubitril because sacubitril/valsartan is shown as ARNI.
||Diuretics other than mineralocorticoid receptor antagonists.
Table 1. Continued
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nearly twice that in patients without diabetes (–2.9 ver-
sus –1.7 mL/min/1.73 m2 per year, P=0.02; Table 2 and 
Figure I in the Data Supplement), but there was no dif-
ference in the rate of decline in eGFR between patients 
with prediabetes and those with normoglycemia (–1.7 
versus –1.8 mL/min/1.73 m2 per year, respectively; Fig-
ure I in the Data Supplement). Furthermore, when the 
study medication was withdrawn to assess the effects 
of double-blind treatment unconfounded by the pres-
ence of an SGLT2 inhibitor, in those allocated to place-
bo, eGFR declined over a median of 16 months by 3.0 
mL/min/1.73 m2 in patients with prediabetes (n=194) 
and by 3.5 mL/min/1.73 m2 in those with normoglyce-
mia and by 5.4 mL/min/1.73 m2 in patients with dia-
betes. The incidence of the composite renal outcome 
was 4.2, 1.9, and 2.2 events per 100 patient-years of 
follow-up in patients with diabetes, prediabetes, and 
normoglycemia, respectively (Figure 5). For the latter 2 
analyses, the decline in renal function and the incidence 
of adverse renal outcomes in the placebo group were 
greater in patients with diabetes, but were similar in 
patients with prediabetes and normoglycemia.
In light of the more rapid decline in glomerular func-
tion in diabetic patients, the magnitude of the effect of 
empagliflozin to slow the rate of decline in eGFR was 
somewhat greater in patients with diabetes than in those 
without diabetes (+2.2 versus +1.3 mL/min/1.73 m2), but 
the treatment-by-diabetes interaction was not significant 
(P=0.15). Furthermore, when the study medication was 
withdrawn to assess the unconfounded effects of dou-
ble-blind treatment, empagliflozin, as compared with 













































































































Figure 1. Effect of empagliflozin on the primary end point of EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure 
With Reduced Ejection Fraction).
Time to first event of either cardiovascular death or heart failure hospitalization in (A) patients with diabetes and (B) patients without diabetes. HR indicates 
hazard ratio.
A B
Figure 2. Effect of empagliflozin on the primary outcome of EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure 
With Reduced Ejection Fraction) by baseline glycohemoglobin (HbA1c) as continuous variable and distribution of HbA1c at baseline in the range 
between 5% and 12%.
A, Effect of empagliflozin on the primary outcome of EMPEROR-Reduced by baseline HbA1c as continuous variable. This figure shows the linear association 
between HbA1c and log hazard ratio for the primary end point. The nonsignificant interaction test (P=0.40) indicates that the slope is not significantly different 
from zero. However, the display makes assumptions about linearity that are difficult to validate, and the slope is strongly influenced by a relatively small number of 
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in patients with diabetes, by 1.3 mL/min/1.73 m2 in pa-
tients with prediabetes, and by 3.1 mL/min/1.73 m2 in 
patients with normoglycemia (P-trend=0.17), indicating 
no influence of baseline HbA1c on the ability of empa-
gliflozin to mitigate the progressive decline in renal func-
tion during double-blind treatment.
Consistent with the lack of effect modification by 
baseline HbA1c on eGFR decline, glycemic status also 
did not modify the benefits of empagliflozin on clini-
cally important renal events. Empagliflozin reduced 
the risk of the composite renal end point by 47% (HR, 
0.53 [95% CI, 0.31–0.90]) in patients with diabetes 
and by 58% in patients without diabetes (HR, 0.42 
[95% CI, 0.19–0.97]), with no significant treatment-
by-diabetes interaction (P=0.65; Table 2 and Figure 4). 
The HRs of the risk reduction in patients with predia-
betes and in patients with normoglycemia were 0.33 
(95% CI, 0.11–1.03) and 0.59 (95% CI, 0.17–2.03), 
respectively; the latter estimate was based on only 11 
events (Figure 5).
Other Efficacy Measures, Vital Signs, and 
Laboratory Tests
The effects of empagliflozin on first hospitalization for 
heart failure and cardiovascular mortality according to 
glycemic status are shown in Figure 5 and Figure II in 
the Data Supplement. The magnitude of the treatment 
effects in patients with or without diabetes was similar 
for these end points as well as for the change in KCCQ 
clinical summary score at 52 weeks in an on-treatment 
analysis (Figure III in the Data Supplement and Table 2).
The effects of empagliflozin on body weight, hemo-
globin, systolic blood pressure, and NT-proBNP accord-
ing to glycemic status are shown in Figures IV–VII in 
the Data Supplement. The magnitude of the treatment 
effects in patients with or without diabetes was simi-
lar. Empagliflozin lowered HbA1c at 52 weeks only in 
patients with diabetes, but not in patients with predia-
betes or normoglycemia; the treatment-by-diabetes in-
teraction was significant (P-trend=0.033; Figure 6 and 
Figure VIII in the Data Supplement).
A B
Figure 3. Effect of empagliflozin on first and recurrent hospitalizations for heart failure.
Effect of empagliflozin on first and recurrent hospitalizations for heart failure in (A) patients with diabetes and (B) patients without diabetes.
A B
Figure 4. Effect of empagliflozin on renal composite end point.
Effect of empagliflozin on renal composite end point in (A) patients with diabetes and (B) patients without diabetes. Composite renal end point is defined as 
chronic dialysis, renal transplant, sustained reduction of ≥40% eGFR, or sustained eGFR <15 mL/min/1.73 m2 for patients with eGFR ≥30 mL/min/1.73 m2 at base-
line (<10 mL/min/1.73 m2 for patients with eGFR <30 mL/min/1.73 m2 at baseline). Dialysis is regarded as chronic if the frequency of dialysis is twice or more per 
week for at least 90 days. In accordance with usual practice, cumulative incidence plots were truncated when the number of patients being followed in individual 
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The study medication was stopped because of ad-
verse events in 147 patients (15.7%) in the empa-
gliflozin group and 152 patients (16.2%) in the pla-
cebo group among patients without diabetes and in 
175 patients (18.9%) in the empagliflozin group and 
176 patients (19.0%) in the placebo group among 
patients with diabetes (Table  3). For adverse events 
other than genital tract infections, there were no 
meaningful increases in the empagliflozin group and 
the pattern of between-group differences was not 
influenced by the presence or absence of diabetes. 
Although confirmed hypoglycemia occurred more fre-
quently in diabetic than nondiabetic patients, no im-
balance between treatment groups was seen. There 
were no episodes of severe hypoglycemia requiring 
assistance in patients without diabetes.
DISCUSSION
Disorders of glycemic control are exceptionally com-
mon in patients with chronic heart failure,9,10 perhaps 
because heart failure itself represents a state of insulin 
resistance,11,12 which is partially driven by the severity 
of the hemodynamic abnormality.13 More than 80% of 
our patients had either diabetes or prediabetes, a prev-
alence similar to that in previous reports on patients 
with heart failure and a reduced ejection fraction.9,10 
In the current trial, compared with patients with heart 
failure and normoglycemia, only patients with diabetes 
showed a marked increase in the risk of heart failure and 
renal events in the absence of treatment with an SGLT2 
inhibitor. Diabetes increased the risk of hospitalizations 
for heart failure by >50% and it nearly doubled the rate 
of decline in eGFR as well as the risk of a major renal 
event. In contrast, the rate of evolution and progression 
of heart failure and kidney disease did not differ among 
patients with prediabetes as compared with those with 
normoglycemia. Our observation regarding the risk of 
heart failure events is consistent with earlier reports 
that when compared with normoglycemia, nondiabetic 
dysglycemia (ie, prediabetes) is associated with little or 
a modest increase in the risk of cardiovascular death 
and heart failure hospitalization in patients with heart 
failure and reduced ejection fraction.9,10 Furthermore, 
Figure 5. Treatment effect of empagliflozin vs placebo on primary and secondary outcomes in patients with normoglycemia, prediabetes, and 
diabetes.
Recurrent event analyses are based on a joint frailty model accounting for competing risk of cardiovascular death. *n corresponds to number of events in recurrent 
event analyses and number of patients with event for time-to-first-event analysis. †Interaction P values from trend test assuming ordered categories. The trend 
test reflects an assumed ordering of the subgroups from normoglycemia to prediabetes to diabetes testing a linear trend across subgroups. ‡Composite renal end 
point: time to first event of chronic dialysis or renal transplant or sustained reduction of ≥40% estimated glomerular filtration rate (eGFR; Chronic Kidney Disease 
Epidemiology Collaboration [CKD-EPI]cr); or for patients with eGFR (CKD-EPI)cr ≥30 mL/min/1.73 m2 at baseline: sustained eGFR <15 mL/min/1.73 m2; for patients 
with eGFR (CKD-EPI)cr <30 mL/min/1.73 m2 at baseline: sustained eGFR <10 mL/min/1.73 m2. An eGFR (CDK-EPI)cr reduction is considered sustained if it is deter-
mined by 2 or more consecutive postbaseline central laboratory measurements separated by at least 30 days (first to last of the consecutive eGFR values). If there 
is no additional measurement ≥30 days after the eGFR reduction is observed and the patient dies within 60 days of this measurement, then the eGFR reduction is 
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our finding regarding the risk of renal disease progres-
sion is consistent with the lack of an increased risk of 
nephropathy in patients with prediabetes who do not 
have heart failure.14,15 Taken collectively, these obser-
vations highlight the importance of distinguishing be-
tween diabetes and prediabetes in the prediction of 
Table 2. Primary and Secondary Outcomes in EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced 
Ejection Fraction) by Diabetes Status
 
Empagliflozin (n=1863) Placebo (n=1867)
HR (95% CI)/slope 
difference (95% CI)
P value for 
interactionn*/N (%)
Incidence rate per 





  Time to first event of cardiovascular death or HHF
   All patients 361/1863 (19.4) 15.77 462/1867 (24.7) 21.00 0.75 (0.65, 0.86)  
   No diabetes 161/936 (17.2) 13.93 197/938 (21.0) 17.59 0.78 (0.64, 0.97) 0.57
   Diabetes 200/927 (21.6) 17.66 265/929 (28.5) 24.55 0.72 (0.60, 0.87)
Key secondary outcomes
  First and recurrent HHF
   All patients 388/1863 — 553/1867 — 0.70 (0.58, 0.85)  
   No diabetes 167/936 — 216/938 — 0.76 (0.57, 1.01) 0.44
   Diabetes 221/927 — 337/929 — 0.65 (0.50, 0.85)
  Mean slope of change in eGFR, mL/min/1.73 m2/y†
   All patients −0.55 — −2.28 — 1.73 (1.10, 2.37)  
   No diabetes −0.45 — −1.72 — 1.27 (0.38, 2.16) 0.15
   Diabetes −0.64 — −2.85 — 2.21 (1.31, 3.10)
Secondary outcomes
  Time to first renal composite outcome‡
   All patients 30/1863 (1.6) 1.56 58/1867 (3.1) 3.07 0.50 (0.32, 0.77)  
   No diabetes 8/936 (0.9) 0.83 19/938 (2.0) 1.99 0.42 (0.19, 0.97) 0.65
   Diabetes 22/927 (2.4) 2.29 39/929 (4.2) 4.17 0.53 (0.31, 0.90)
  Time to first HHF
   All patients 246/1863 (13.2) 10.75 342/1867 (18.3) 15.55 0.69 (0.59, 0.81)  
   No diabetes 106/936 (11.3) 9.17 141/938 (15.0) 12.59 0.72 (0.56, 0.93) 0.66
   Diabetes 140/927 (15.1) 12.36 201/929 (21.6) 18.62 0.67 (0.54, 0.83)
  Time to cardiovascular death
   All patients 187/1863 (10.0) 7.55 202/1867 (10.8) 8.13 0.92 (0.75, 1.12)  
   No diabetes 83/936 (8.9) 6.69 89/938 (9.5) 7.20 0.92 (0.68, 1.24) 0.98
   Diabetes 104/927 (11.2) 8.42 113/929 (12.2) 9.06 0.92 (0.71, 1.20)
Change in KCCQ clinical 
summary score§ at 52 
weeks (on-treatment)










Difference in change 
(95% CI)
 
   All patients 77.51 (0.44) 5.83 (0.44) 75.77 (0.44) 4.09 (0.45) 1.75 (0.5, 3.0)  
   No diabetes 77.87 (0.62) 5.43 (0.62) 76.77 (0.63) 4.33 (0.63) 1.10 (−0.64, 2.85) 0.30
   Diabetes 76.59 (0.63) 6.58 (0.63) 74.19 (0.64) 4.17 (0.64) 2.41 (0.64, 4.17)  
Recurrent event analyses are based on a joint frailty model accounting for competing risk of cardiovascular death or all-cause mortality, respectively. HHF indicates 
hospitalization for heart failure; HR, hazard ratio; and KCCQ, Kansas City Cardiomyopathy Questionnaire.
*n corresponds to number of events in recurrent event analyses and number of patients with event for time to first event analysis.
†Estimated glomerular filtration rate (eGFR) slope is analyzed based on the treated set considering measurements until end of treatment.
‡Composite renal end point: time to first event of chronic dialysis or renal transplant or sustained reduction of ≥40% eGFR (Chronic Kidney Disease Epidemiology 
Collaboration [CKD-EPI]cr); or for patients with eGFR (CKD-EPI)cr ≥30 mL/min/1.73 m2 at baseline: sustained eGFR <15 mL/min/1.73 m2; for patients with eGFR 
(CKD-EPI)cr <30 mL/min/1.73 m2 at baseline: sustained eGFR <10 mL/min/1.73 m2. An eGFR (CDK-EPI)cr reduction is considered sustained if it is determined by 2 or 
more consecutive postbaseline central laboratory measurements separated by at least 30 days (first to last of the consecutive eGFR values). If there is no additional 
measurement ≥30 days after the eGFR reduction is observed and the patient dies within 60 days of this measurement, then the eGFR reduction is also considered 
sustained.
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end-organ injury, even in patients with heart failure and 
a reduced ejection fraction.
Empagliflozin reduced the risk of the primary out-
come variables as well as total hospitalizations for heart 
failure by 25% to 30% and treatment with the drug 
slowed the rate of decline in eGFR during double-blind 
therapy and reduced the risk of serious adverse events 
by 50%. The benefits were seen in patients with or 
without diabetes and the magnitude of these favorable 
effects was not influenced by the baseline HbA1c level. 
The effect of empagliflozin on heart failure and renal 
outcomes was such that treatment with the drug ef-
fectively negated the deleterious effect of diabetes on 
the risk of heart failure and renal events. For the primary 
outcome of cardiovascular death or hospitalization for 
heart failure, the event rate per 100 patient-years of fol-
low-up among patients with diabetes was reduced from 
24.6 in the placebo group to 17.7 in the empagliflozin 
group, a risk similar to that seen in patients with nor-
moglycemia who received placebo (ie, 16.5). For total 
hospitalizations for heart failure, the event rate per 100 
patient-years among those with diabetes was reduced 
from 27.2 in the placebo group to 18.0 in the empa-
gliflozin group, a risk similar to that seen in patients with 
normoglycemia who received placebo (ie, 16.9). For the 
composite renal end point, the event rate per 100 pa-
tient-years of follow-up among patients with diabetes 
was reduced from 4.2 to 2.3 by empagliflozin; the latter 
risk was similar to that seen in patents with normoglyce-
mia who were treated with placebo (ie, 2.2).
Beyond lowering excess risk associated with dia-
betes, treatment with empagliflozin also reduced the 
risk of heart failure and renal events in patients with 
prediabetes and normoglycemia. The magnitude of 
the benefit in nondiabetic patients was similar to that 
in patients with diabetes and the heart failure and re-
nal benefits of empagliflozin were consistent across a 
broad range of baseline values for HbA1c. Consistent 
with its known mechanism of action to lower blood 
glucose only in the setting of hyperglycemia, empa-
gliflozin only reduced HbA1c in patients with diabetes 
and not in patients with prediabetes or normoglycemia. 
These findings strongly underscore the conclusion that 
the benefits of empagliflozin on the heart and the kid-
neys are not related to the level of dysglycemia or to 
changes in glycohemoglobin. The precise mechanism 
of action of SGLT2 inhibitors to lower the risk of heart 
failure events remains to be defined, but given our find-
ings, the pathophysiologic abnormalities that are ame-
liorated by empagliflozin are not dependent on or are 
unlikely to be meaningfully influenced by abnormalities 
in blood glucose.4 It is therefore noteworthy that vari-
ous biomarkers of the effect of empagliflozin in heart 
failure (ie, changes in body weight, natriuretic peptides, 
and hemoglobin) were influenced to a similar degree in 
patients with or without diabetes.
There were no meaningful imbalances in tolerability 
or safety events between the empagliflozin and place-
bo groups among patients with heart failure with and 
without diabetes. Adverse effects that are typical of 
other heart failure medications (such as hyperkalemia 
and hypotension) were observed similarly in the pla-
cebo and empagliflozin groups. No reports of diabetic 
ketoacidosis or severe hypoglycemic episode occurred 




















































































































Figure 6. Glycohemoglobin changes from baseline by glycemic status.
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Table 3. Adverse Events of Interest by Diabetes Status
 
Empagliflozin (n=1863) Placebo (n=1863)
n/N (%)
Incidence rate per 
100 patient-years n/N (%)
Incidence rate per 
100 patient-years
Patients with SAE
  No diabetes 375/936 (40.1) 42.6 439/937 (46.9) 52.8
  Diabetes 397/927 (42.8) 45.1 457/926 (49.4) 57.6
Patients with AE leading to discontinuation
  No diabetes 147/936 (15.7) 13.0 152/937 (16.2) 13.5
  Diabetes 175/927 (18.9) 15.6 176/926 (19.0) 15.8
Hypotension
  No diabetes 85/936 (9.1) 7.93 91/937 (9.7) 8.61
  Diabetes 91/927 (9.8) 8.51 72/926 (7.8) 6.78
Volume depletion
  No diabetes 94/936 (10.0) 8.84 100/937 (10.7) 9.54
  Diabetes 103/927 (11.1) 9.68 84/926 (9.1) 7.99
Acute renal failure
  No diabetes 77/936 (8.2) 7.07 94/937 (10.0) 8.74
  Diabetes 98/927 (10.6) 9.20 98/926 (10.6) 9.29
Confirmed* hypoglycemic event
  Normoglycemic 1/304 (0.3) 0.27 1/302 (0.3) 0.26
  Prediabetes 6/632 (0.9) 0.79 5/635 (0.8) 0.67
  Diabetes 20/927 (2.2) 1.79 22/926 (2.4) 2.00
Severe† hypoglycemic event
  Normoglycemic 0/304 — 0/302 —
  Prediabetes 0/632 — 0/635 —
  Diabetes 6/927 (0.6) 0.53 7/926 (0.8) 0.63
Diabetic ketoacidosis
  Normoglycemic 0/304 — 0/302 —
  Prediabetes 0/632 — 0/635 —
  Diabetes 0/927 — 0/926 —
Lower limb amputation
  No diabetes 1/936 (0.1) 0.08 1/937 (0.1) 0.08
  Diabetes 12/927 (1.3) 0.94 9/926 (1.0) 0.70
Fractures
  No diabetes 25/936 (2.7) 2.23 16/937 (1.7) 1.42
  Diabetes 20/927 (2.2) 1.79 26/926 (2.8) 2.36
Hyperkalemia events‡
  No diabetes 48/936 (5.1) 4.37 53/937 (5.7) 4.87
  Diabetes 61/927 (6.6) 5.67 74/926 (8.0) 7.01
Genital infections
  No diabetes 13/936 (1.4) 1.15 8/937 (0.9) 0.71
  Diabetes 18/927 (1.9) 1.62 4/926 (0.4) 0.36
Urinary tract infection
  No diabetes 39/936 (4.2) 3.52 34/937 (3.6) 3.06
  Diabetes 52/927 (5.6) 4.74 49/926 (5.3) 4.47
Adverse events (AEs) are shown up to 7 days after discontinuation of study medication, but lower limb amputations are shown for the 
total period. Search for specified AEs of interest was based on the predefined list of preferred terms. SAE indicates serious adverse event.
*Defined as hypoglycemic AEs with a plasma glucose value of ≤70 mg/dL or that required assistance.
†Defined as a hypoglycemic episode requiring assistance.




 http://ahajournals.org by on January 26, 2021
Anker et al Empagliflozin in HFrEF With or Without Diabetes 














with empagliflozin in patients with prediabetes or nor-
moglycemia. This shows the favorable benefit–risk pro-
file of empagliflozin and provides reassurance to clini-
cians in initiating SGLT2 inhibitors in patients with heart 
failure who do not have diabetes.
Our findings should be considered in light of both 
strengths and limitations of the current trial. Each of our 
major end points was prespecified and the analysis of the 
effect of empagliflozin in patients with and without dia-
betes was designated as our most important subgroup 
analysis. The patients without diabetes comprised a sub-
stantial proportion of our population (50%) and we were 
also able to study the effect of empagliflozin in a consider-
able number of patients with prediabetes. Because insulin 
resistance is exceptionally common in heart failure and a 
reduced ejection fraction, we expected that the propor-
tion of patients with normoglycemia would be compara-
tively small, leading to estimates of a treatment effect in 
patients with normoglycemia that were necessarily less 
precise. However, when comparing the magnitude of the 
treatment effect across the 3 glycemia subgroups, there 
was a remarkable consistency of the benefit of empa-
gliflozin with no evidence for heterogeneity.
In this secondary analysis of EMPEROR-Reduced, em-
pagliflozin significantly reduced the risk of cardiovas-
cular death or heart failure hospitalizations, decreased 
total hospitalizations for heart failure, slowed decline in 
renal function, prevented serious renal events, and im-
proved measures of health status to a similar degree in 
patients with and without diabetes. Our findings rein-
force those recently reported in a similar trial with dapa-
gliflozin in heart failure with reduced ejection fraction, 
but we extend those findings to include benefits on the 
evolution of renal disease as well as defined benefits 
in patients with prediabetes and no glycemic disorder. 
The combined results of the 2 trials reinforce a new role 
for SGLT2 inhibitors in patients with heart failure and 
reduced ejection fraction independent of diabetes or 
the baseline level of glycohemoglobin.
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